Selective prostacyclin IP receptor antagonist (pKi
= 8.3). Exhibits no affinity at other prostanoid receptors (EP1-4
, FP and TP) in a radioligand binding assay. Demonstrates analgesic activity in rats. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists.
Clark et al.
Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.
Jones et al.
RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.
Bley et al.